Related Experiment Videos
A homogeneous cell-based assay to identify N-linked carbohydrate processing inhibitors
A Datti1, R S Donovan, B Korczak
1GlycoDesign Inc., Toronto, Ontario, Canada. adatti@glycodesign.com
Abstract:
Malignant transformation is accompanied by altered cell surface glycosylation. N-Linked oligosaccharides carrying beta1-6GlcNAc branches are associated with tumor invasion and metastasis. Therefore, compounds that can enter cells and block biosynthesis of beta1-6GlcNAc-branched glycans without overt cytotoxicity are potential anticancer agents. We have developed a homogeneous cell-based assay for detection of such compounds. The method enables identification of agents that block beta1-6GlcNAc-branched glycan expression after incubation for 16-20 h with MDAY-D2 tumor cells, thereby protecting the cells from the subsequent addition of leukoagglutinin, a cytotoxic plant lectin. We observed that MDAY-D2 cell number is directly proportional to the level of endogenous alkaline phosphatase activity measured spectrophotometrically in cultures after the addition of substrate. The alkaline phosphatase assay was capable of detecting as few as 1,500 cells. The assay was readily adapted for high-throughput screening as reagent costs are low and no cell harvesting and washing steps are required. Under high-throughput operating conditions, the coefficient of variation for controls was found to be 4.2%. The results suggest that measurement of alkaline phosphatase in this cell assay format may be adapted for wider applications in high-throughput screenings for compounds that relieve cells from other growth inhibitors.
Insights
Researchers developed a cell-based assay to find anticancer drugs that block sugar molecule (beta1-6GlcNAc-branched glycan) production. This assay identifies compounds that protect tumor cells from a toxic lectin, aiding cancer research.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Malignant transformation involves changes in cell surface glycosylation.
- N-linked oligosaccharides with beta1-6GlcNAc branches correlate with tumor invasion and metastasis.
Purpose of the Study:
- To develop a cell-based assay for identifying compounds that inhibit beta1-6GlcNAc-branched glycan biosynthesis.
- To find potential anticancer agents that block specific glycan structures without causing significant cell death.
Main Methods:
- A homogeneous cell-based assay using MDAY-D2 tumor cells was developed.
- The assay detects compounds that block beta1-6GlcNAc-branched glycan expression by assessing protection against the cytotoxic plant lectin leukoagglutinin.
- Alkaline phosphatase activity, which is proportional to cell number, was measured spectrophotometrically to quantify cell viability.
Main Results:
- The assay successfully identified agents that inhibit beta1-6GlcNAc-branched glycan expression.
- The alkaline phosphatase assay could detect as few as 1,500 cells.
- The assay demonstrated adaptability for high-throughput screening with a coefficient of variation of 4.2% for controls.
Conclusions:
- The developed cell-based assay is effective for screening compounds that inhibit beta1-6GlcNAc-branched glycan biosynthesis.
- This assay format shows potential for broader applications in high-throughput screening for compounds targeting other cellular growth inhibitors.